CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,302,476 | -56.1% | 36,200 | -45.6% | 0.00% | -62.5% |
| Q4 2022 | $2,968,362 | -12.1% | 66,600 | -44.5% | 0.01% | -20.0% |
| Q3 2022 | $3,376,000 | -45.5% | 120,100 | -47.8% | 0.01% | -44.4% |
| Q2 2022 | $6,198,000 | +18.2% | 229,900 | +49.3% | 0.02% | +28.6% |
| Q1 2022 | $5,245,000 | +125.1% | 154,000 | +155.4% | 0.01% | +133.3% |
| Q4 2021 | $2,330,000 | -20.6% | 60,300 | -31.3% | 0.01% | -25.0% |
| Q2 2021 | $2,934,000 | -32.3% | 87,736 | -58.3% | 0.01% | -33.3% |
| Q1 2021 | $4,331,000 | -38.4% | 210,256 | -47.6% | 0.01% | -36.8% |
| Q4 2020 | $7,035,000 | +7.0% | 401,556 | -9.4% | 0.02% | 0.0% |
| Q3 2020 | $6,575,000 | +801.9% | 443,356 | +690.9% | 0.02% | +850.0% |
| Q2 2020 | $729,000 | +1870.3% | 56,056 | +239.8% | 0.00% | – |
| Q4 2019 | $37,000 | -14.0% | 16,497 | -19.1% | 0.00% | – |
| Q3 2019 | $43,000 | -40.3% | 20,397 | -24.4% | 0.00% | – |
| Q2 2019 | $72,000 | -51.0% | 26,997 | -9.7% | 0.00% | – |
| Q1 2019 | $147,000 | – | 29,897 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |